share_log

Goldman Sachs Initiates Coverage On Tarsus Pharmaceuticals With Neutral Rating, Announces Price Target of $19

Benzinga ·  Nov 20, 2023 04:43

Goldman Sachs analyst Andrea Tan initiates coverage on Tarsus Pharmaceuticals (NASDAQ:TARS) with a Neutral rating and announces Price Target of $19.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment